2020 Year in Review: Non–Small-Cell Lung Cancer
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512